secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001193125-25-045568
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio secures up to $250M in debt and royalty financing for taletrectinib
--------------------------------------------------------------------------------

- $100M loan with Sagard; initial $50M tranche upon FDA approval of taletrectinib by Sep 30, 2025; second $50M upon first US commercial sale by Jun 30, 2026
- Loan matures Sep 30, 2030, interest SOFR (4% floor) + 6% quarterly; prepayment premiums; $25M minimum cash covenant
- $150M revenue interest financing; tiered royalties: 5.5% on US net sales up to $600M, 3.0% on $600M-$1B, none above $1B
- Royalty obligation ends at 1.6x-2.0x investment amount; true-up if not repaid by Feb 1, 2043
- Company can buy out royalty at 140%-200% of investment amount less payments made; investor can put upon certain events

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525045568/0001193125-25-045568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312525045568/d918004d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-045568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer